FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046804491> ?p ?o ?g. }

• W2046804491 endingPage "ix69" @default.
• W2046804491 startingPage "ix69" @default.
• W2046804491 abstract "Background: Chemotherapies for non-small cell lung cancer (NSCLC) patients with interstitial pneumonia (IP) give rise to considerable problems of developing lung injuries and exacerbations of IP. Clinical benefits and risks of chemotherapies for such conditions are not fully evaluated.Objective and methods: To elucidate detailed clinical conditions and outcomes, advanced (stage IIIB/IV) NSCLC patients with IP who had been treated in our clinic from 2009 to 2012 were examined retrospectively.Results: A total of 180 patients was analyzed. Nineteen cases (13 adenocarcinomas, 6 Squamous cell carcinomas) had IP (10.6%), 16 cases (84.2%) were smokers. One case showed EGFR gene mutation. Sixteen patients (84.2%) underwent chemotherapies; median survivals were 12.5 months (M) in patients who received 2 regimens, 21.2 M in those received over 3 regimens, and 2.0 M in those not received, respectively. Platinum-based regimens have been mostly chosen (84.2%). EGFR-TKIs were used in 5 cases (31.3%); 2 cases (40%) with EGFR-TKI developed interstitial lung disease (ILD). Another case with DTX aborted chemotherapy due to exacerbation of IP. Thus, a total of 3 patients (15.8%) developed ILD, however no patients died of ILD. Median survivals were 2.0 M in patients with IPF (n = 3), 46.0 M in CPFE (n = 6), and 12.7 M in others (n = 10), respectively. Patients with IP showed poorer prognosis than those without IP regardless of tumor histology.Conclusions: Chemotherapies were beneficial even for these patients. Careful observations and immediate treatments for ILD would reduce severe adverse events. Background: Chemotherapies for non-small cell lung cancer (NSCLC) patients with interstitial pneumonia (IP) give rise to considerable problems of developing lung injuries and exacerbations of IP. Clinical benefits and risks of chemotherapies for such conditions are not fully evaluated. Objective and methods: To elucidate detailed clinical conditions and outcomes, advanced (stage IIIB/IV) NSCLC patients with IP who had been treated in our clinic from 2009 to 2012 were examined retrospectively. Results: A total of 180 patients was analyzed. Nineteen cases (13 adenocarcinomas, 6 Squamous cell carcinomas) had IP (10.6%), 16 cases (84.2%) were smokers. One case showed EGFR gene mutation. Sixteen patients (84.2%) underwent chemotherapies; median survivals were 12.5 months (M) in patients who received 2 regimens, 21.2 M in those received over 3 regimens, and 2.0 M in those not received, respectively. Platinum-based regimens have been mostly chosen (84.2%). EGFR-TKIs were used in 5 cases (31.3%); 2 cases (40%) with EGFR-TKI developed interstitial lung disease (ILD). Another case with DTX aborted chemotherapy due to exacerbation of IP. Thus, a total of 3 patients (15.8%) developed ILD, however no patients died of ILD. Median survivals were 2.0 M in patients with IPF (n = 3), 46.0 M in CPFE (n = 6), and 12.7 M in others (n = 10), respectively. Patients with IP showed poorer prognosis than those without IP regardless of tumor histology. Conclusions: Chemotherapies were beneficial even for these patients. Careful observations and immediate treatments for ILD would reduce severe adverse events." @default.
• W2046804491 created "2016-06-24" @default.
• W2046804491 creator A5011406390 @default.
• W2046804491 creator A5054204404 @default.
• W2046804491 creator A5058133640 @default.
• W2046804491 creator A5065170136 @default.
• W2046804491 creator A5084821253 @default.
• W2046804491 date "2013-11-01" @default.
• W2046804491 modified "2023-10-17" @default.
• W2046804491 title "Efficacy and Safety of Chemotherapies for Advanced Non-Small Cell Lung Cancer Patients with Interstitial Pneumonia" @default.
• W2046804491 doi "https://doi.org/10.1093/annonc/mdt460.17" @default.
• W2046804491 hasPublicationYear "2013" @default.
• W2046804491 type Work @default.
• W2046804491 sameAs 2046804491 @default.
• W2046804491 citedByCount "0" @default.
• W2046804491 crossrefType "journal-article" @default.
• W2046804491 hasAuthorship W2046804491A5011406390 @default.
• W2046804491 hasAuthorship W2046804491A5054204404 @default.
• W2046804491 hasAuthorship W2046804491A5058133640 @default.
• W2046804491 hasAuthorship W2046804491A5065170136 @default.
• W2046804491 hasAuthorship W2046804491A5084821253 @default.
• W2046804491 hasBestOaLocation W20468044911 @default.
• W2046804491 hasConcept C126322002 @default.
• W2046804491 hasConcept C143998085 @default.
• W2046804491 hasConcept C146357865 @default.
• W2046804491 hasConcept C151730666 @default.
• W2046804491 hasConcept C2776256026 @default.
• W2046804491 hasConcept C2776694085 @default.
• W2046804491 hasConcept C2777014857 @default.
• W2046804491 hasConcept C2777543607 @default.
• W2046804491 hasConcept C2777714996 @default.
• W2046804491 hasConcept C71924100 @default.
• W2046804491 hasConcept C86803240 @default.
• W2046804491 hasConcept C90924648 @default.
• W2046804491 hasConceptScore W2046804491C126322002 @default.
• W2046804491 hasConceptScore W2046804491C143998085 @default.
• W2046804491 hasConceptScore W2046804491C146357865 @default.
• W2046804491 hasConceptScore W2046804491C151730666 @default.
• W2046804491 hasConceptScore W2046804491C2776256026 @default.
• W2046804491 hasConceptScore W2046804491C2776694085 @default.
• W2046804491 hasConceptScore W2046804491C2777014857 @default.
• W2046804491 hasConceptScore W2046804491C2777543607 @default.
• W2046804491 hasConceptScore W2046804491C2777714996 @default.
• W2046804491 hasConceptScore W2046804491C71924100 @default.
• W2046804491 hasConceptScore W2046804491C86803240 @default.
• W2046804491 hasConceptScore W2046804491C90924648 @default.
• W2046804491 hasLocation W20468044911 @default.
• W2046804491 hasOpenAccess W2046804491 @default.
• W2046804491 hasPrimaryLocation W20468044911 @default.
• W2046804491 hasRelatedWork W1987468340 @default.
• W2046804491 hasRelatedWork W2055244776 @default.
• W2046804491 hasRelatedWork W2234805389 @default.
• W2046804491 hasRelatedWork W2348529436 @default.
• W2046804491 hasRelatedWork W2356105190 @default.
• W2046804491 hasRelatedWork W2390152934 @default.
• W2046804491 hasRelatedWork W2413020017 @default.
• W2046804491 hasRelatedWork W2898146382 @default.
• W2046804491 hasRelatedWork W2908163910 @default.
• W2046804491 hasRelatedWork W3142039466 @default.
• W2046804491 hasVolume "24" @default.
• W2046804491 isParatext "false" @default.
• W2046804491 isRetracted "false" @default.
• W2046804491 magId "2046804491" @default.
• W2046804491 workType "article" @default.